<DOC>
	<DOC>NCT00634933</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.</brief_summary>
	<brief_title>Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.525 mg weekly) for at least 12 weeks with or without a history of antiTNF use. Any prior use of rituximab or other B cell depleting agents. Any significant health problem other than rheumatoid arthritis Clinically significant laboratory abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>active</keyword>
	<keyword>rheumatoid</keyword>
	<keyword>arthritis</keyword>
	<keyword>anti CD20</keyword>
</DOC>